Document Detail


Hormonal, blood pressure, and peritoneal transport response to short-term ACE inhibition.
MedLine Citation:
PMID:  7827189     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: To evaluate the hormonal, blood pressure, and peritoneal transport effects of intraperitoneal enalaprilat and oral enalapril. DESIGN: A nonrandomized, nonblinded, prospective clinical trial was performed. SETTING: The study was conducted at the Clinical Research Unit at the Medical College of Virginia, a tertiary care center. PATIENTS: Six continuous ambulatory peritoneal dialysis (CAPD) patients with hypertension were enrolled in the study. All 6 patients received intraperitoneal enalaprilat. Five of the patients also received oral enalapril. INTERVENTIONS: Hormonal, clinical, and transport parameters were investigated in patients given intraperitoneal enalaprilat and oral enalapril. Standardized 2-L exchanges were performed during a control period, following 2.5 mg intraperitoneal enalaprilat and after a week of oral enalapril. Inulin, blood urea nitrogen (BUN) and creatinine clearances, and glucose absorption were determined during these exchanges. RESULTS: After intraperitoneal enalaprilat, both systolic and diastolic blood pressure significantly declined, reaching maximal decreases of -21.7 +/- 14.2% at 95 +/- 92 minutes, and of -23.3 +/- 15.4% at 105 +/- 105 minutes, respectively. Plasma angiotensin converting enzyme (ACE) activity was suppressed below detectable limits at four hours following intraperitoneal enalaprilat, and remained suppressed throughout all sampling time points following oral enalapril treatment. There was no significant change in drain volumes, glucose absorption, or BUN, creatinine, or inulin clearances, whether enalaprilat was administered intraperitoneally or enalapril orally. CONCLUSION: This study demonstrates that intraperitoneal administration of enalaprilat is a rapidly effective route of administration of this ACE inhibitor. There were no changes in peritoneal transport characteristics demonstrated.
Authors:
E B Ripley; T W Gehr; C W Kish; D A Sica
Related Documents :
6229379 - Reversal of left ventricular hypertrophy with captopril: heterogeneity of response amon...
8845089 - Duration of action of angiotensin converting enzyme inhibitors.
12929469 - Very-low-dose combination: a first-line choice for the treatment of hypertension?
7018859 - The effects of captopril on blood pressure in essential hypertensive patients with low ...
8961069 - Circadian variation in blood pressure and heart rate in nonhypertensive congestive hear...
2686089 - Observations with captopril (tensiomin) treatment in hypertensive patients (one-year pe...
1480839 - Viscoelastic properties of the visceral pleura and its contribution to lung impedance.
20433539 - Relationship of hypertension, blood pressure, and blood pressure control with white mat...
9377729 - Accelerated (malignant) hypertension: a study of 121 cases between 1974 and 1996.
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis     Volume:  14     ISSN:  0896-8608     ISO Abbreviation:  Perit Dial Int     Publication Date:  1994  
Date Detail:
Created Date:  1995-02-23     Completed Date:  1995-02-23     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  8904033     Medline TA:  Perit Dial Int     Country:  CANADA    
Other Details:
Languages:  eng     Pagination:  378-83     Citation Subset:  IM    
Affiliation:
Department of Nephrology, Medical College of Virginia, Virginia Commonwealth University, Richmond.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Adult
Aldosterone / blood*
Biological Transport
Blood Pressure / drug effects*
Enalapril / administration & dosage*
Enalaprilat / administration & dosage*
Female
Humans
Hypertension / blood,  drug therapy*,  physiopathology
Male
Peptidyl-Dipeptidase A / blood
Peritoneal Dialysis, Continuous Ambulatory*
Peritoneum / metabolism*
Prospective Studies
Renin / blood*
Grant Support
ID/Acronym/Agency:
MO1-RR00065/RR/NCRR NIH HHS
Chemical
Reg. No./Substance:
52-39-1/Aldosterone; 75847-73-3/Enalapril; 84680-54-6/Enalaprilat; EC 3.4.15.1/Peptidyl-Dipeptidase A; EC 3.4.23.15/Renin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Viscus perforation in peritoneal dialysis patients: diagnosis and outcome.
Next Document:  Is the Durie and Salmon diagnostic classification system for plasma cell dyscrasias still the best c...